Four new policies under development may address a variety of lingering regulatory hurdles for foreign drug and device companies in China.
China Market Intelligence
A Note to Members from Craig Allen May 10th, 2021
Q1 2021 Bilateral Trade Update May 5th, 2021
The Senate’s Sweeping Proposal to Compete with China May 5th, 2021
China’s Legislative Priorities for 2021: Data, Privacy, Competition, and Liberalizing Hainan May 5th, 2021